Investor Presentation - First Six Months of 2021
47
Investor presentation First six months of 2021
The global GLP-1 market penetration varies across regions with
Novo Nordisk having a best-in-class marketed portfolio
GLP-1 market growth and Novo Nordisk market share
GLP-1 value and patient share¹ of the total diabetes market
70%
60%
50%
40%
30%
20%
10%
0%
0%
World
30%
28%
61%
24%
25%
51%
20%
31%
15%
25%
10%
7%
5%
16%
ÜLL..
8%
5% 4%
May
2018
May
2021
NN market share
NN share of growth
Market growth
NN growth
America
■GLP-1 value share of total diabetes
■GLP-1 patient share of total diabetes
North
EMEA
Region
China
ROW
1Patient share based on data for the USA, the UK, Germany and France only.
Note: EMEA: Europe, Middle East and Africa; Row: Rest of World
Source: IQVIA MAT value (Spot rate), May 2021
Novo NordiskⓇView entire presentation